Patents by Inventor Mikkel Askjær AGERSNAP

Mikkel Askjær AGERSNAP has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250073311
    Abstract: The invention relates to a dosage regime for compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors for use in the treatment of obesity and related conditions.
    Type: Application
    Filed: September 2, 2022
    Publication date: March 6, 2025
    Inventor: Mikkel Askjær AGERSNAP
  • Publication number: 20240091317
    Abstract: The present invention relates to dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), in patients with renal insufficiency. Unlike other GLP-2 analogues, such as teduglutide, it has been found that ZP1848 is cleared normally in patients with renal impairment. As a result, there is no need to adjust the dosage of ZP1848 depending on a patient's renal function.
    Type: Application
    Filed: December 15, 2021
    Publication date: March 21, 2024
    Inventors: Kim SONNE, Mikkel Askjær AGERSNAP, Kim Mark KNUDSEN